Quarterly ResultMay 14, 2026, 04:32 PM
Edesa Biotech Q2 Net Loss $4.2M; Vitiligo & ARDS Programs Advance
AI Summary
Edesa Biotech reported financial results for the three and six months ended March 31, 2026, showing increased net losses primarily due to higher operating expenses for clinical trial preparations. The company's net loss for Q2 2026 was $4.2 million, or $0.49 per share, up from $1.6 million in the prior year. Concurrently, Edesa provided positive business updates, including being on track for its Phase 2 clinical study of EB06 in vitiligo and additional positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome, reinforcing confidence in its pipeline.
Key Highlights
- Q2 2026 net loss was $4.2 million, or $0.49 per common share, compared to $1.6 million ($0.30/share) in Q2 2025.
- H1 2026 net loss was $6.5 million, or $0.78 per common share, compared to $3.2 million ($0.74/share) in H1 2025.
- Total operating expenses increased by $2.7 million to $4.3 million in Q2 2026.
- R&D expenses increased by $2.3 million to $2.8 million in Q2 2026, driven by EB06 and paridiprubart.
- G&A expenses increased by $0.3 million to $1.5 million in Q2 2026.
- Vitiligo program (EB06) Phase 2 clinical study preparations are on track for midyear 2026 patient recruitment.
- Additional positive Phase 3 data for paridiprubart in ARDS showed consistent treatment benefits.
- Cash and cash equivalents were $10.0 million and working capital was $8.2 million as of March 31, 2026.